CNST - Constellation Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Constellation Pharmaceuticals, Inc.

215 First Street
Suite 200
Cambridge, MA 02142
United States
617-714-0555
http://www.constellationpharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees82

Key Executives

NameTitlePayExercisedYear Born
Mr. Jigar RaythathaPres, CEO & Director637.13kN/AN/A
Ms. Emma ReeveSr. VP, CFO, Treasurer & Sec.645.96kN/A1961
Dr. Adrian M. Senderowicz M.D.Sr. VP & Chief Medical Officer555.06kN/A1964
Dr. Danny Reinberg Ph.D.Co-FounderN/AN/AN/A
Dr. Yang Shi Ph.D.Co-FounderN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. It is also developing CPI-0209, which is in preclinical trials for the treatment of solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.

Corporate Governance

Constellation Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 10. The pillar scores are Audit: 3; Board: 10; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.